Dendritic Cell Immunotherapy for Glioblastoma Treatment

Dendritic cell immunotherapy harnesses the antigen‐presenting capacity of dendritic cells to initiate and amplify tumour‐specific immune responses against glioblastoma, the most aggressive primary brain malignancy. In this approach, dendritic cells are harvested from the patient, loaded ex vivo with tumour antigens derived from autologous tumour lysate or defined peptides, and reinfused under adjuvant regimens designed to enhance their maturation and migration to lymphoid tissues. Upon reintroduction, these cells present antigens to naïve T lymphocytes, driving the activation and clonal expansion of cytotoxic T cells capable of crossing the blood–brain barrier and targeting residual tumour cells. Clinical studies have investigated combinations with standard treatments—surgical resection, radiotherapy and temozolomide—to address the immunosuppressive tumour microenvironment and exploit synergistic effects. Despite challenges related to antigen heterogeneity, central nervous system immunosuppression and variable patient responses, dendritic cell vaccines have demonstrated safety, immunogenicity and, in some trials, extension of progression-free and overall survival. Ongoing research focuses on optimising adjuvant selection, improving antigen loading strategies and integrating novel immune-modulating agents to overcome tumour-induced tolerance and improve durable outcomes.

Research from Nature Portfolio

Recent studies have demonstrated that incorporating toll-like receptor agonists with autologous tumour lysate-pulsed dendritic cell vaccines can polarise systemic interferon responses in patients with malignant glioma. In a randomised phase II trial, the addition of poly-ICLC to dendritic cell vaccination was safe and led to augmented interferon-induced gene expression in circulating monocytes and activated CD8+ T lymphocytes. Enhanced interferon signatures correlated with prolonged survival and delayed disease progression, suggesting that the choice of adjuvant can serve both as a potent immunomodulator and a predictive blood biomarker for vaccine efficacy.

Dendritic Cell Immunotherapy for Glioblastoma Treatment publication trend

The graph below shows the total number of articles in dendritic cell immunotherapy for glioblastoma treatment across all publications each year (not limited to Nature Index journals).

Technical terms

Dendritic cell: A type of antigen‐presenting immune cell that processes and presents tumour antigens to T lymphocytes to initiate adaptive immune responses.

Tumour lysate: A preparation of broken tumour cells containing a broad spectrum of tumour‐associated antigens used to load dendritic cells for vaccination.

Adjuvant: A substance co-administered with a vaccine that enhances the magnitude and quality of the immune response.

Toll-like receptor agonist: A molecule that stimulates innate immune receptors on dendritic cells, promoting their activation and cytokine production.

Interferon response: A programme of gene expression induced by interferon cytokines that enhances antigen presentation and antiviral or antitumour immune activity.

References

1. TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial. Nature Communications (2024).
2. Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma. JAMA Oncology (2023).
3. Glioblastoma vaccines: past, present, and opportunities. EBioMedicine (2024).